Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis

Open access

Abstract

Pulmonary fibrosis is characterized by fibroblast proliferation and extracellular matrix remodelling, leading to respiratory insufficiency. The mechanisms underlying this progressive and devastating disease remain unclear. Conditions that can impair the function of the endoplasmic reticulum (ER) cause accumulation of unfolded or misfolded proteins, resulting in ER stress and activation of the unfolded protein response (UPR). ER stress has been implicated in many conditions including cancer, diabetes, obesity, and inflammation. It is also involved in lung fibrosis, through myofibroblastic differentiation of fibroblasts; however, the precise role of ER stress in lung fibrosis is unknown. The current study aimed to investigate the underlying mechanisms of ER stress inhibitors in the treatment of bleomycin-induced lung fibrosis. We demonstrated that bleomycin can activate ER stress associated proteins, including GRP78, CHOP, and ATF-4, both in vitro and in vivo. PI3K/AKT acts upstream of ER stress to affect lung fibroblast proliferation, resulting in bleomycin-induced pulmonary fibrosis. Treatment with ER stress inhibitors or a PI3K inhibitor caused a reduction in fibroblast proliferation and improved pulmonary function. The relationship between PI3K/AKT/mTOR and ER stress in pulmonary fibrosis, and the application of PI3K inhibitors and ER stress inhibitors in the treatment of pulmonary fibrosis require further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-017-14612-5

Cites

Statistics

Figures

Figure 1 Bleomycin-induced pulmonary fibrosis was associated with ER stress activation. Mice with intratracheal administration of bleomycin (2 U/kg) or saline (vehicle) were sacrificed 14 days later and the lung specimens were harvested for (A Left) histological analysis with HE, Picro Sirius red and Masson’s trichrome staining followed by (A Right) quantification, (B) The results of total collagen assay, (C) Western blot analysis (Cropped blots are displayed; Full-length blots are presented in Supplementary Figure, labeled Figure S1), and (D) immunofluorescence for the expression of proteins associated with ER stress activation.
Figure 1 Bleomycin-induced pulmonary fibrosis was associated with ER stress activation. Mice with intratracheal administration of bleomycin (2 U/kg) or saline (vehicle) were sacrificed 14 days later and the lung specimens were harvested for (A Left) histological analysis with HE, Picro Sirius red and Masson’s trichrome staining followed by (A Right) quantification, (B) The results of total collagen assay, (C) Western blot analysis (Cropped blots are displayed; Full-length blots are presented in Supplementary Figure, labeled Figure S1), and (D) immunofluorescence for the expression of proteins associated with ER stress activation.CC BY · PubMed Central
Figure 2 Bleomycin-induced pulmonary fibrosis was attenuated by treatment with ER stress inhibitors. (A) Flow chart of the experimental procedure. Mice with intratracheal administration of bleomycin (2 U/kg) or saline (vehicle) were treated with or without 4-PBA or TUDCA before (Upper: prevention) or 7 days (Lower: treatment) after bleomycin intratracheal instillation. The mice were sacrificed 14 days later and the lung specimens were harvested for histological analysis with (B) HE, (C) picro pirius red and (D) Masson’s trichrome staining followed by (C and D Right) quantification, (E) The results of total collagen assay and (F) Western blot analysis (Cropped blots are displayed; Full-length blots are presented in Supplementary Figure, labeled Figure S2) for the expression of proteins associated with ER stress activation.
Figure 2 Bleomycin-induced pulmonary fibrosis was attenuated by treatment with ER stress inhibitors. (A) Flow chart of the experimental procedure. Mice with intratracheal administration of bleomycin (2 U/kg) or saline (vehicle) were treated with or without 4-PBA or TUDCA before (Upper: prevention) or 7 days (Lower: treatment) after bleomycin intratracheal instillation. The mice were sacrificed 14 days later and the lung specimens were harvested for histological analysis with (B) HE, (C) picro pirius red and (D) Masson’s trichrome staining followed by (C and D Right) quantification, (E) The results of total collagen assay and (F) Western blot analysis (Cropped blots are displayed; Full-length blots are presented in Supplementary Figure, labeled Figure S2) for the expression of proteins associated with ER stress activation.CC BY · PubMed Central
Figure 3 Bleomycin induced ER stress and AKT activation in murine lung fibroblast culture. (A–D) Cells before or indicated time period after treatment with indicated concentration of bleomycin were subjected to western blot analysis for the expression of proteins associated with (A,B) ER stress or (D) AKT activation, and (C) cell number counting (24 hours). (E–G) Cells were treated without (CTR) or with bleomycin in the absence or presence of ER stress or PI3K inhibitor for 6 hours, followed by western blot analysis for the expression of proteins associated with (E) ER stress or (F) AKT activation. (G) Cells transfected with control, PERK, ATF6 and IRE1 shRNA were treated without or with bleomycin for 6 hours, followed by western blot analysis. (Cropped blots are displayed; Full-length blots are presented in Supplementary Figure, labeled Figure S3B and C).
Figure 3 Bleomycin induced ER stress and AKT activation in murine lung fibroblast culture. (A–D) Cells before or indicated time period after treatment with indicated concentration of bleomycin were subjected to western blot analysis for the expression of proteins associated with (A,B) ER stress or (D) AKT activation, and (C) cell number counting (24 hours). (E–G) Cells were treated without (CTR) or with bleomycin in the absence or presence of ER stress or PI3K inhibitor for 6 hours, followed by western blot analysis for the expression of proteins associated with (E) ER stress or (F) AKT activation. (G) Cells transfected with control, PERK, ATF6 and IRE1 shRNA were treated without or with bleomycin for 6 hours, followed by western blot analysis. (Cropped blots are displayed; Full-length blots are presented in Supplementary Figure, labeled Figure S3B and C).CC BY · PubMed Central
Figure 4 Treatment of ER stress inhibitors reduced pulmonary fibrosis and expression of p-AKT and p-mTOR in vivo. Mice with intratracheal administration of bleomycin (2 U/kg) or saline (vehicle) were treated with or without 4-PBA (500 mg/kg, i.p.) or TUDCA (500 mg/kg, i.p.) before (prevention) or 7 days (treatment) after bleomycin intratracheal instillation. The mice were sacrificed 14 days later and the lung specimens were harvested for (A,B,D) immunohistochemical analysis, (C) immunofluorescence, (E) Western blot analysis of lung harvested from Mice before or indicated time periods after intratracheal administration of bleomycin (2 U/kg) and (F) western blot analysis with or without treatment of 4-PBA and TUDC, (Cropped blots are displayed; Full-length blots are presented in Supplementary Figure, labeled Figure S4).
Figure 4 Treatment of ER stress inhibitors reduced pulmonary fibrosis and expression of p-AKT and p-mTOR in vivo. Mice with intratracheal administration of bleomycin (2 U/kg) or saline (vehicle) were treated with or without 4-PBA (500 mg/kg, i.p.) or TUDCA (500 mg/kg, i.p.) before (prevention) or 7 days (treatment) after bleomycin intratracheal instillation. The mice were sacrificed 14 days later and the lung specimens were harvested for (A,B,D) immunohistochemical analysis, (C) immunofluorescence, (E) Western blot analysis of lung harvested from Mice before or indicated time periods after intratracheal administration of bleomycin (2 U/kg) and (F) western blot analysis with or without treatment of 4-PBA and TUDC, (Cropped blots are displayed; Full-length blots are presented in Supplementary Figure, labeled Figure S4).CC BY · PubMed Central
Figure 5 Bleomycin-induced pulmonary fibrosis was attenuated by treatment with PI3K inhibitor. (A) Flow chart of the experimental procedure. Mice with intratracheal administration of bleomycin (2 U/kg) or saline (vehicle) were treated with or without PI3K inhibitor, LY294002 (LY, 50 mg/kg, i.p.) before (Upper: prevention) or 7 days (Lower: treatment) after bleomycin intratracheal instillation. The mice were sacrificed 14 days later and the lung specimens were harvested for histological analysis with (B) HE, (C) picro pirius red and (D) Masson’s trichrome staining followed by (C and D Right) quantification, (E) the results of total collagen assay, (F and G) immunohistochemical analysis, and (H,I) Western blot analysis for the expression of proteins associated with (H) AKT and (I) ER stress after treatment of PI3K inhibitor, LY294002, in control, prevention and treatment groups. (Cropped blots are displayed; Full-length blots are presented in Supplementary Figure, labeled Figure S5).
Figure 5 Bleomycin-induced pulmonary fibrosis was attenuated by treatment with PI3K inhibitor. (A) Flow chart of the experimental procedure. Mice with intratracheal administration of bleomycin (2 U/kg) or saline (vehicle) were treated with or without PI3K inhibitor, LY294002 (LY, 50 mg/kg, i.p.) before (Upper: prevention) or 7 days (Lower: treatment) after bleomycin intratracheal instillation. The mice were sacrificed 14 days later and the lung specimens were harvested for histological analysis with (B) HE, (C) picro pirius red and (D) Masson’s trichrome staining followed by (C and D Right) quantification, (E) the results of total collagen assay, (F and G) immunohistochemical analysis, and (H,I) Western blot analysis for the expression of proteins associated with (H) AKT and (I) ER stress after treatment of PI3K inhibitor, LY294002, in control, prevention and treatment groups. (Cropped blots are displayed; Full-length blots are presented in Supplementary Figure, labeled Figure S5).CC BY · PubMed Central
Figure 6 PTEN inhibitor activated the PI3K/AKT pathway in murine lung fibroblast culture and also induced pulmonary fibrosis in vivo. (A,B) Cells treated with or without PTEN inhibitor bpV (pic) for 24 hours were subjected to (A) western blot analysis (Cropped blots are displayed; Full-length blots are presented in Supplementary Figure, labeled Figure S6), and (B) cell number counting (24 hours). (C–E) Mice with intratracheal administration of bpV (2.5 mm) were sacrificed 1, 3 or 7 days later and the lung specimens were harvested for histological analysis with (C) HE, (D) picro pirius red and (E) Masson’s trichrome staining followed by (D and E Right) quantification, (F) The results of total collagen assay.
Figure 6 PTEN inhibitor activated the PI3K/AKT pathway in murine lung fibroblast culture and also induced pulmonary fibrosis in vivo. (A,B) Cells treated with or without PTEN inhibitor bpV (pic) for 24 hours were subjected to (A) western blot analysis (Cropped blots are displayed; Full-length blots are presented in Supplementary Figure, labeled Figure S6), and (B) cell number counting (24 hours). (C–E) Mice with intratracheal administration of bpV (2.5 mm) were sacrificed 1, 3 or 7 days later and the lung specimens were harvested for histological analysis with (C) HE, (D) picro pirius red and (E) Masson’s trichrome staining followed by (D and E Right) quantification, (F) The results of total collagen assay.CC BY · PubMed Central
Figure 7 Pulmonary function in bleomycin-induced pulmonary fibrosis was improved by treatment with ER stress and PI3K inhibitors. (A,B) Barometric plethysmography was conducted in mice before or 14 days after intratracheal administration of bleomycin (2 U/kg) or saline (vehicle), treated with or without (A) 4-PBA or TUDCA (500 mg/kg, i.p.), or (B) PI3K inhibitor, LY294002 (LY, 50 mg/kg, i.p.) before (prevention) or 7 days (treatment) after bleomycin intratracheal instillation. (C) Barometric plethysmography was conducted in mice before or indicated time periods after intratracheal administration of bpV (2.5 mm).
Figure 7 Pulmonary function in bleomycin-induced pulmonary fibrosis was improved by treatment with ER stress and PI3K inhibitors. (A,B) Barometric plethysmography was conducted in mice before or 14 days after intratracheal administration of bleomycin (2 U/kg) or saline (vehicle), treated with or without (A) 4-PBA or TUDCA (500 mg/kg, i.p.), or (B) PI3K inhibitor, LY294002 (LY, 50 mg/kg, i.p.) before (prevention) or 7 days (treatment) after bleomycin intratracheal instillation. (C) Barometric plethysmography was conducted in mice before or indicated time periods after intratracheal administration of bpV (2.5 mm).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 27 · Cited by 205

Metadata

Authors
Hsu, H.-S., Liu, C.-C., Lin, J.-H., Hsu, T.-W., Hsu, J.-W., Su, K., & Hung, S.-C.
Affiliations
  • Taipei Veterans General Hospital (TW)
  • China Medical University (TW)
Corresponding author
  • Hsu, Han-Shui
  • Hung, Shih-Chieh
Venue
Scientific Reports
Published
2017-10-27
Volume
7
Issue
1
Pages
14272-14272
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2766645546
Cited by
205
References
27
Citations by year
2026: 8 · 2025: 25 · 2024: 21 · 2023: 22 · 2022: 30 · 2021: 48 · 2020: 25 · 2019: 12 · 2018: 14
FWCI
11.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Academia Sinica
  • Ministry of Science and Technology, Taiwan (MOST103-2321-B010-018, MOST103-2321-B010-024)
  • Taipei Veterans General Hospital (V106C-060)
  • Institute of Biomedical Sciences, Academia Sinica
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
pulmonary fibrosis, bleomycin-induced lung fibrosis, endoplasmic reticulum stress, unfolded protein response, PI3K/Akt signaling, lung fibroblast proliferation, GRP78, CHOP, ATF4, ER stress inhibitors, PI3K inhibitors, mTOR, extracellular matrix remodeling
MeSH terms
Endoplasmic Reticulum Chaperone BiP, Animals, Bleomycin, Cell Line, Enzyme Activation, Fibroblasts, Heat-Shock Proteins, Lung, Pulmonary Fibrosis, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Mice, Activating Transcription Factor 4, Transcription Factor CHOP, Unfolded Protein Response, Endoplasmic Reticulum Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. https://app.cochat.ai/papers/10.1038/s41598-017-14612-5
The paper
Hsu, H.-S., Liu, C.-C., Lin, J.-H., Hsu, T.-W., Hsu, J.-W., Su, K., & Hung, S.-C. (2017). Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. Scientific Reports. https://doi.org/10.1038/s41598-017-14612-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.